Results 11 to 20 of about 15,436 (169)

Amyloid cardiomyopathy [PDF]

Biomedical Papers, 2017
Amyloidosis is a heterogeneous group of diseases characterized by the deposition of amyloid. It is caused by extracellular deposition of insoluble fibrils with beta-pleated sheet configuration.
Lucie Karafiatova, Tomas Pika
doaj   +6 more sources

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure
Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction. This study
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
doaj   +2 more sources

Diagnosis of Transthyretin Amyloid Cardiomyopathy [PDF]

Cardiology and Therapy, 2020
Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis.
Adam S. Hafeez, Anthony A. Bavry
doaj   +3 more sources

Hereditary transthyretin amyloid cardiomyopathy

Singapore Medical Journal, 2023
10.4103/singaporemedj.SMJ-2021-300 ; Singapore medical journal ; 64 ; 1 ; 74 ...
Yiliang Zheng, Ching-Hui Sia, Raymond Ching Chew Wong, Roger Sik Yin Foo, Weiqin Lin, Devinder Singh, Yoke Ching Lim   +6 more
doaj   +3 more sources

Recurrent Syncope, a Clue in Amyloid Cardiomyopathy

Case Reports in Medicine, 2018
Infiltrative cardiomyopathies include a variety of disorders that lead to myocardial thickening resulting in a constellation of clinical manifestations and eventually heart failure that could be the first clue to reach the diagnosis.
Julian A. Marin-Acevedo, Catalina Sanchez-Alvarez, Ali A. Alsaad, Ricardo J. Pagán   +3 more
doaj   +3 more sources

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy

Arquivos Brasileiros de Cardiologia, 2016
Background: Amyloidosis is a disease caused by deposits of insoluble fibrils in extracellular spaces. The most common type of familial amyloidosis is mediated by mutation of transthyretin, especially Val30Met.
Alexandre Marins Rocha, Suzane Garcia Ferreira, Marcelo Souto Nacif, Mario Luiz Ribeiro, Marcos Raimundo Gomes de Freitas, Cláudio Tinoco Mesquita   +5 more
doaj   +5 more sources

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Several imaging parameters and biomarkers provide diagnostic and prognostic information for wild‐type transthyretin amyloid cardiomyopathy.
Mami Morioka, Seiji Takashio, Naoya Nakashima, Masato Nishi, Akira Fujiyama, Kyoko Hirakawa, Shinsuke Hanatani, Hiroki Usuku, Eiichiro Yamamoto, Masafumi Kidoh, Seitaro Oda, Kenichi Matsushita, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +1 more source

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2022
Background:Beta-adrenergic antagonists or blockers (BB) are a cornerstone of cardiac therapy for multiple indications. However, BB are considered relatively contraindicated in amyloid cardiomyopathy due to poor tolerance. This intolerance is hypothesized
Stuart Ramsell, Carlos Arias Bermudez, Cyril Ayuk Mbeng Takem Baiyee, Brandon Rodgers, Samir Parikh, Salem Almaani, Nidhi Sharma, Samantha LoRusso, Miriam Freimer, Elyse Redder, Naresh Bumma, Ajay Vallkati, Yvonne Efebera, Rami Kahwash, Courtney M. Campbell, Courtney M. Campbell   +15 more
doaj   +1 more source

Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio

ESC Heart Failure, 2021
Amyloid light chain (AL) cardiomyopathy is the most malignant specific cardiomyopathy. According to international recommendations, it should be ruled out non‐invasively using the serum free light chain (FLC) ratio and immunofixation electrophoresis in ...
David Zach, Klemens Ablasser, Ewald Kolesnik, Viktoria Hoeller, Friedrich Fruhwald, Florian Prüller, Clemens Reiter, Christine Beham‐Schmid, Rainer Lipp, Peter P. Rainer, Andreas Zirlik, Albert Wölfler, Nicolas Verheyen   +12 more
doaj   +1 more source

Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene

Stem Cell Research, 2023
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease caused by the abnormal production of misfolded TTR protein by liver cells, which is then released systemically.
Pilar Montero-Calle, María Flandes-Iparraguirre, Bernd Kuebler, Begoña Arán, Eduardo Larequi, Ilazki Anaut, Giulia Coppiello, Xabier L. Aranguren, Anna Veiga, Maria Teresa Basurte Elorz, Manuel García de Yébenes, Juan J. Gavira, Felipe Prósper, Olalla Iglesias-García, Manuel M. Mazo Vega   +14 more
doaj   +1 more source